Expression of Y-box-binding protein dbpC/contrin, a potentially new cancer/testis antigen by Kohno, Y et al.








1,4 and Y Sasaguri
1
1Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
2Department of
Ophthalmology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
3Department of Molecular Biology, School
of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;
4Department of Surgical Pathology, Kyushu Koseinenkin Hospital,
Kitakyushu, Japan
Y-box-binding proteins are members of the human cold-shock domain protein superfamily, which includes dbpA, dbpB/YB-1, and
dbpC/contrin. dbpC/contrin is a germ cell-specific Y-box-binding protein and is suggested to function as a nuclear transcription factor
and RNA-binding protein in the cytoplasm. Whereas ubiquitous dbpB/YB-1 expression has been well studied in various types of
human carcinomas as a prognostic or predictive marker, the dbpC/contrin expression in human tumour cells has not been reported.
In this report, we provide the first evidence showing that dbpC was highly expressed in human testicular seminoma and ovarian
dysgerminomas, and in carcinomas in other tissues and that its expression in normal tissues is nearly restricted to germ cells and
placental trophoblasts. These results indicate that dbpC/contrin would be a potentially novel cancer/testis antigen.
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Y-box-binding proteins are nucleic acid-binding proteins and are
members of the human cold-shock domain protein superfamily
(CSPs), which includes dbpA, dbpB/YB-1, and dbpC/contrin
(Kohno et al, 2003). The CSPs are eukaryotic homologues of
bacterial cold-shock proteins, which function as RNA chaperones
(Matsumoto and Wolffe, 1998). Human heat-shock proteins have
been well studied; however, much is not known about the
functional roles of cold-shock proteins. In general, the cold-shock
response includes growth arrest and a reduction in protein
synthesis in bacteria (Jolly and Morimoto, 2000). The eukaryotic
Y-box-binding proteins have been not known to be involved in the
cold-shock response; however, recent study indicated a block in
cell proliferation after low-temperature shift in YB-1 knockout
chicken cell line (Matsumoto et al, 2005).
The Y-box-binding proteins participate in various reactions,
including DNA repair, transcription, and translation (Kohno et al,
2003). Of the human Y-box-binding protein family members,
dbpB/YB-1 was first described in 1988 as a ubiquitously expressed
transcriptional factor that can bind to the CCAAT-box of the major
histocompatibility complex (MHC) class II promoter (Didier et al,
1988). The dbpA gene was first identified in 1988 (Sakura et al,
1988) and cloned in 1995, encoding a protein highly expressed in
skeletal muscle (Kudo et al, 1995), and that of dbpC/contrin was
cloned in 1999 as coding for a testis-specific protein distinct from
other Y-box-binding proteins (Tekur et al, 1999). The ubiquitous
expression of the dbpB/YB-1 gene in human normal and neoplastic
tissues has been well studied and found to be closely associated
with the expression of p-glycoprotein, the product of the multidrug
resistance 1 (MDR1) gene, in breast cancers (Bargou et al, 1997),
osteosarcomas (Oda et al, 1998), ovarian cancers (Kamura et al,
1999), and synovial sarcomas (Oda et al, 2003). It is also associated
with the expression of DNA topoisomerase II and proliferating cell
nuclear antigen in colon (Shibao et al, 1999) and lung (Gu et al,
2001) cancers. Thus, the nuclear localisation of dbpB/YB-1 is
significantly related to malignant behaviour, and, consequently,
this transcriptional factor is a tumour-biologic factor indicating a
poor prognosis (Janz et al, 2002).
In contrast, the expression of dbpA was first reported to be
restricted to the heart and skeletal muscles (Kudo et al, 1995). It
functions as a transcriptional repressor of MHC I-A and vascular
endothelial growth factor genes (Lloberas et al, 1995; Coles et al,
2002). A recent report indicated somatic mutations and single-
nucleotide pleomorphism in the promoter of dbpA to be
associated with hepatocarcinogenesis (Hayashi et al, 2002). On
the other hand, dbpC/contrin is a germ cell-specific Y-box-binding
protein and is suggested to function as a nuclear transcription
factor and RNA-binding protein in the cytoplasm (Tekur et al,
1999). However, its expression and distribution have not been
studied in human neoplastic tissues. In the present study,
therefore, we investigated the expression and distribution of the
dbpA and dbpC/contrin in human normal and neoplastic tissues
by using antibodies raised against C-terminal synthetic peptides of
these proteins.
We demonstrated that dbpC, but not dbpA, was highly
expressed in human normal spermatogonia/spermatocytes,
oocytes, and placental trophoblasts as well as in testicular
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sseminoma, ovarian dysgerminomas, and various histological types
of human cancer tissues. Therefore, a possibility is suggested that
the dbpC would be a novel cancer/testis (C/T) antigen and also a
marker for cancer stem cells.
MATERIALS AND METHODS
Preparation of human tissue samples
Normal human tissue samples of general organs were obtained
from three autopsy cases and from non-tumour parts of surgically
resected specimens (Table 1). For human neoplastic tissue
samples, 123 cases of surgically resected tumours including 21
germ cell tumours of ovarian and testicular origin were examined
in the Department of Pathology and Cell Biology at University of
Occupational and Environmental Health in Kitakyushu, Japan
(Tables 2 and 3). These cases were classified according to the
World Health Organization Histological Typing of each tissue. The
diagnosis was re-evaluated and confirmed by at least three board-
certified surgical pathologists who had examined formalin-fixed,
paraffin-embedded tissue sections stained with haematoxylin and
eosin (H&E) or appropriate immunohistochemical stains.
Preparation of antibodies against CSPs
Polyclonal antibodies were raised against dbpA and dbpC/contrin by
multiple immunisation of New Zealand white rabbits with synthetic
peptides. The sequence of the synthetic peptide for dbpA was
CGKEAKAGEAPTEN, and that for dbpC/contrin, CAPVNSGDPTT
TILE. The specificity of the antibodies was confirmed by Western
blotting and immunostain with peptide competition (not shown).
Immunohistochemistry of tissue samples
Immunohistochemical staining was performed by using the
antibody-linked dextran polymer method (Envision, DAKO,
Tokyo). Deparaffinised and rehydrated 5-mm sections were
antigen-retrieved by heating them in Target retrieval solution
(DAKO) for 20min, and then incubating them in 3% H2O2 for
10min to block endogenous peroxidase activity. The sections were
thereafter rinsed and incubated with rabbit polyclonal anti-CSPs
antibodies. The second antibody/peroxidase-linked polymers were
then applied, and the sections were incubated with a solution
consisting of 20mg of 3.30-diaminobenzidine tetrahydrochloride,
65mg of sodium azide, and 20ml of 30% H2O2 in 100ml of Tris-
HCl (50mmoll
 1, pH 7.6). After having been counterstained with
Meyer’s haematoxylin, the sections were observed under a light
microscope. For the CSP immunohistochemistry of normal human
Table 1 Distribution of dbps in human normal tissue
dbpA dbpC
Ovary
Oocyte   +++
Granulosa cell   
Testis
Spermatogonia and spermatocyte + +++
Sertoli cell   
Leydig cell +  
Uterus   
Fallopian tube   
Oesophagus +  
Stomach +  
Small intestine   
Large intestine   
Liver   
Pancreas   
Lung – arterial smooth muscle   +
Heart ++ +
Skeletal muscle ++ +
Aorta   
Renal tubules   
Bladder   
Spleen   
Bone marrow – megakaryocytes   
Thymus   
Brain   
Spinal cord   
Thyroid gland   
Adrenal gland   
Cortex – reticular zone + +
Decidual cell ++  
Trophoblast   ++
Table 2 Expression of dbpA and dbpC in cancer tissues
dbpA dbpC
Organ Histology Cases + ++ +++ + ++ +++
Ovary Serous adenocarcinoma 10 1 0 0 2 0 0
Stomach Adenocarcinoma 10 0 0 0 2 3 0
Colon Adenocarcinoma 10 0 0 0 2 7 0
Liver Hepatocellular carcinoma 10 0 0 0 0 0 0
Cholangiocellular carcinoma 10 1 1 0 2 6 0
Breast Invasive ductal carcinoma 10 0 0 0 2 3 0
Pancreas Adenocarcinoma 10 0 0 0 4 2 0
Kidney Clear cell carcinoma 10 1 0 0 1 0 0
Prostate Adenocarcinoma 10 0 0 0 4 0 0
Lung Adenocarcinoma 10 0 0 0 0 0 0
Squamous cell carcinoma 10 0 0 0 3 3 0
Total cases 110 3 1 0 22 24 0
Testis Seminoma 10 0 0 0 0 0 10
Ovary Dysgerminoma 3 0 0 0 0 0 3
Total cases 13 0 0 0 0 0 13
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stissues, the intensity of the immunohistochemical reaction was
graded into four categories: ( ), cells with negative staining; (þ),
cells with a low staining intensity; (þþ), cells with moderately
stronger intensity than (þ) but less than (þþþ); (þþþ),
cells with a marked staining intensity. For the neoplastic tissues,
positive areas comprising less than 10% of the neoplasms were
considered as negative staining. Positive areas that were equal to or
more than 10% were defined as positive staining and were graded
into three categories: (þ), positive area of 10–30%; (þþ),
30–80%; (þþþ), more than 80% positive area.
Cell cultures
Human seminoma cell lines Tera1 (ATCC HTB-105), NEC8
(JCRB0250), choriocarcinoma cell line NJG (IFO50322), and breast
cancer cell line MCF7 cell (ATCC HTB-22) were obtained from
American Type Culture Collection (Rockville, MD, USA) and
maintained in RPMI1640 medium containing 10% fetal calf serum
(ICN, Costa Mesa, CA, USA) at 371C in an atmosphere of 95% air
and 5% CO2.
Immunocytochemistry of seminoma cell line NEC8
Human seminoma NEC8 cells were cultured on coverslips, fixed
with 95% acetone for 5min, and allowed to air dry. The cells were
then incubated with anti-dbp antibodies for 1h at room
temperature (RT), washed with PBS, and reacted with fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG for 1h at RT. After
having been washed with PBS, the specimens were observed under
a Nikon fluorescence microscope.
To investigate the subcellular localisation of the dbpC protein,
we transfected human seminoma cells (NEC8) by lipofection
(Gibco BRL, Grand Island, NY, USA) with plasmids expressing
dbpC fused to green fluorescent protein (GFP-dbpC). The cells
were cultured for 24h after the transfection and then observed
under the fluorescence microscope.
Cell fractionation and Western blotting
Cells (2 10
7) were resuspended in 2ml of ice-cold 10mM HEPES-
KOH (pH 7.9) containing 10mmoll
 1 KCl, 0.1mmoll
 1 EDTA,
0.1mmoll
 1 EGTA, 1mmoll
 1 dithiothreitol, and 0.5mmoll
 1
phenylmethylsulphonyl fluoride (PMSF) and incubated on ice for
15min. The cells were then lysed by the dropwise addition of 0.6%
NP-40, and the lysates were centrifuged at 400g for 10min at 41C.
The supernatant was used as the cytoplasmic fraction, and the
nuclear pellet was resuspended in 300ml of ice-cold 20mmoll
 1
HEPES-KOH (pH 7.9) containing 0.4moll
 1 NaCl, 1mmoll
 1
EDTA, 1mmoll
 1 dithiothreitol, and 1mmoll
 1 PMSF and
incubated for 15min on ice with frequent gentle mixing followed
Table 3 Expression of dbps in human germ cell tumours
Case Age Sex Primary site Histological type dbpA dbpC
1 12 F Ovary Dysgerminoma   +++
2 34 F Ovary Dysgerminoma   +++
3 27 F Ovary Dysgerminoma   +++
4 43 M Testis Seminoma   +++
5 53 M Testis Seminoma   +++
6 40 M Testis Seminoma   +++
7 28 M Testis Seminoma   +++
8 50 M Testis Seminoma   +++
9 38 M Testis Seminoma   +++
10 44 M Testis Seminoma   +++
11 43 M Testis Seminoma   +++
12 36 M Testis Seminoma   +++
13 25 M Testis Seminoma   +++
14 33 M Testis Seminoma   +++
Yolk sac tumour   +
Embryonal carcinoma   +
15 37 M Testis Seminoma   +++
Yolk sac tumour   +
Embryonal carcinoma   
Immature teratoma   
16 31 F Ovary Yolk sac tumour   
17 28 M Testis Yolk sac tumour   +
Choriocarcinoma   
Immature teratoma   
18 39 F Ovary Choriocarcinoma   
19 31 M Testis Yolk sac tumour   +
Choriocarcinoma   
20 43 M Testis Yolk sac tumour   +
Embryonal carcinoma   
Immature teratoma   
21 28 M Testis Yolk sac tumour   +
Mature teratoma   
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sby centrifugation for 5min at 41C to remove insoluble materials.
The resulting supernatant was taken as the nuclear fraction. The
proteins in the cytoplasmic and nuclear fractions (100mg) were
separated by 10% SDS–polyacrylamide gel electrophoresis and
transferred onto a polyvinylidene fluoride membrane. The
membrane was immunoblotted with anti-CSP antibodies (diluted
1:3000) for 1h and then developed by chemiluminescence using
the ECL kit (Amersham, Piscataway, NJ, USA).
RESULTS
Expression of Y-box-binding proteins in normal human
tissues (Figure 1 and Table 1)
For detection of dbpA and dbpC expression in normal human
tissues, non-tumour areas of surgically resected tumours and
tissues from autopsy cases were examined immunohistochemi-
cally. The dbpA protein was predominantly distributed in the
cardiomyocytes and striated muscle cells (not shown). In the ovary
and testis, dbpA was expressed in the spermatocytes located in the
inner area of the seminiferous tubules but not in oocytes (Figure 1).
The dbpC/contrin protein was markedly expressed in oocytes and
testicular germ cells in the stage of spermatogonia to spermatocyte,
some of which showed nuclear localization of the protein. The
vascular smooth muscle cells in the pulmonary artery, myo-
cardium, and skeletal muscle were also (þ) positive for dbpC (not
shown), but epithelial cells in respiratory, gastrointestinal, and
urogenital tracts were negative. Placental trophoblasts were also
positive for dbpC (not shown). The results on the immuno-
localisation of these dbps in normal human tissues are summarised
in Table 1.
Expression of dbpA and dbpC in human carcinomas in
various organs (Figure 2 and Table 2)
As the expression of dbpB/YB-1 has been well studied in many
types of human carcinoma cells (Bargou et al, 1997; Oda et al,
1998; Kamura et al, 1999; Shibao et al, 1999; Gu et al, 2001; Oda
et al, 2003), we focused on the expression of dbpA and dbpC in
human tumour cells in this report. We collected the cancer tissues
of the alimentary and respiratory tracts, breast, kidney, prostate,
and ovary (10 cases each). As a result, no dbpA was detected in
these cancer cells, except for two rare cases of cholangiocellular
carcinoma, one renal cell carcinoma, and one ovarian serous
cystadenocarcinoma, in which the degree of positive staining was
(þ)o r(þþ). In contrast, dbpC was expressed in many types of
carcinoma cells at a relatively higher frequency than for dbpA;
however, all staining was (þ)o r(þþ). The frequency of dbpC-
positive tumours varied among the histological types. Hepato-
cellular carcinomas and lung adenocarcinomas were negative in all
10 cases, whereas adenocarcinomas of the colon and cholangio-
cellular carcinomas exhibited higher frequencies for expressing
dbpC (nine out of 10 and eight out of 10, respectively). In total,
approximately 40% (46 out of 110) of the carcinomas were positive
for dbpC. Even in the negative cases (less than 10% positive cells),
however, scattered individual cells were positive for dbpC in the
most carcinoma tissues examined (not shown). Figure 2 shows a
representative case of dbpC-positive ovarian serous cystadeno-
carcinoma. The results for all carcinomas examined are summarised
in Table 2.
Expression of dbpA and dbpC in human germ cell tumours
(Figure 3 and Table 3)
All the testicular seminomas and ovarian dysgerminomas tested
(cases 1–13), as well as seminoma components in testicular mixed
germ cell tumours (cases 14 and 15), showed strong (þþþ)
granular cytoplasmic staining with anti-dbpC antibody, whereas
they were negative for dbpA (Figure 3). In other types of germ cell
tumours, for example, the tumour cells of yolk sac tumours (cases
14–21) and embryonal carcinoma (case 14), positive immuno-
reactions for dbpC were focal; however, the cells of choriocarci-




Figure 1 Expression of dbpA and dbpC in normal human testis and
ovary. Note the extensive expression of dbpC in the spermatogonia to
spermatocytes and in the oocytes. Some cells show a nuclear localisation of
the dbpC protein. Sertoli cells (arrowheads) and spermatids (arrows in the
inset) are negative for the dbps. On the other hand, the cells located in the
inner parts of the seminiferous tubules (spermatocytes) are positive for
dbpA.
H&E dbpA dbpC
Figure 2 Expression of dbpA and dbpC in a human ovarian
adenocarcinoma. The carcinoma cells are weakly positive for dbpC, but
negative for dbpA.
H&E dbpA dbpC
Figure 3 Expression of dbpA and dbpC in human testicular seminoma.
This H&E section demonstrates a typical feature of testicular seminoma.
The dbpC protein, but not dbpA, is intensely expressed in the cytoplasm of
the tumour cells.
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sresults of immunohistochemistry for dbpA and dbpC in the germ
cell tumours are summarised in Table 3.
Analysis of dbpC expression in human seminoma cell lines
The immunofluorescence staining of the seminoma cell lines
showed marked expression of dbpC in the cytoplasm, but only
weak expression for dbpA and dbpB (NEC8 in Figure 4A). Western
blotting analysis showed cytoplasmic distribution of dbpC protein
in both seminoma cell lines examined (NEC8 and Tera), whereas
dbpB was localised in both cytoplasmic and nuclear fractions
(Figure 4B). When NEC8 cells were transfected with plasmids
expressing the GFP-dbpC fusion protein, the green fluorescence
was mainly localised in the cytoplasm, indicating a predominant
localisation of dbpC even in the condition of overexpression
(Figure 4C).
DISCUSSION
The expression of many genes is regulated at the level of
transcription during embryogenesis and spermatogenesis. Trans-
lational control, however, represents a major mechanism of gene
regulation in germ cell differentiation and early embryogenesis
and in late spermatogenesis (Ritcher, 1993; Schafer et al, 1995;
Hecht, 1998). Germ cells store masked mRNAs, and the unmasking
of the mRNAs for protein synthesis plays an important role in the
meiotic progression of oocytes to eggs and in the late stage of
spermatogenesis (Hecht, 1995; Eddy and O’Brien, 1997). This
translational control is likely to be regulated by a number of RNA-
binding proteins (Cooke and Elliott, 1997). dbpC, a mammalian
homologue of the Xenopus germ cell-specific Y-box protein, may
serve a similar function, as it is present exclusively in postmeiotic
round spermatids in rodent testis and in diplotene-stage and
mature oocytes (Gu et al, 1999; Tekur et al, 1999). Recently,
growing numbers of genes that are expressed in male germ cells
and malignancies have been designated as CT genes, by which a
common functional pathway between spermatogenesis and tumor-
igenesis (e.g. progression of meiosis and polyploidy, respectively)
would be explainable (Old, 2001; Simpson et al, 2005). Therefore,
the study of the expression of dbpC in malignancies might provide
clues for understanding the shared characters between spermato-
genesis and tumorigenesis.
Here, we demonstrated for the first time that dbpC is
highly expressed in human normal germ cells and trophoblasts,
but rarely in no-germline normal tissues, as well as testicular
seminomas, ovarian dysgerminomas, and many cancer cells in
other organs.
Expression of dbps in normal and neoplastic tissues
The present study showed unique distribution of the dbpA and
dbpC proteins in normal human tissues. dbpA was distributed in
the heart, skeletal muscle, and decidual cells, whereas dbpC was
predominantly localised in testicular and ovarian germ cells, and
in trophoblasts (Table 1). In the human testis, dbpC was expressed
intensely in the cells undergoing transition from spermatogonia to
spermatocytes. In the neoplastic tissue, dbpA was detected in only
a few carcinoma cases among more than 100 cancer cases. In
contrast, dbpC was extensively expressed in the seminomas and
dysgerminomas. In other organs, many types of cancers were also
positive for dbpC (Tables 2 and 3). Thus, dbpC showed restricted
expression in normal tissues but a wide distribution in malig-
nancies. This contrasts well with the ubiquitous expression of
dbpB in normal and neoplastic cells (Kohno et al, 2003).
dbpC as a potential cancer/testis antigen
Antigens that show expression restricted to normal testicular germ
cells, trophoblasts, and malignancies are designated as CT antigens
(Old, 2001; Scanlan et al, 2004; Kalejs and Erenpreisa, 2005;
Simpson et al, 2005). As features in germ cells corresponding to
those in cancer cells include immortalisation to transformation,
meiosis to aneuploidy, and migration to metastasis, it is thought
that genetic alteration in cancer cells is the result of the activation
of normally silent germline genes. The CT genes support the theory
that the aberrant expression of germline genes in cancer cells
reflects the reactivation of the silenced gametogenic programmes
in terms of tumorigenesis (Simpson et al, 2005). At present, 44 CT
antigen families are known to be expressed in testicular
spermatogonia, spermatocytes, or spermatids and in malignancies
of various histological types including lung, gastrointestinal,
urogenital cancers (Jungbluth et al, 2000, 2002; Scanlan et al,
2004; Kalejs and Erenpreisa, 2005). The biological function of CT
antigens in either germ cells or cancer cells is not yet clearly
understood; however, some of the CT antigens are suggested to be
translational or transcriptional regulatory factors or RNA-binding
proteins (Simpson et al, 2005).
On the other hand, the dbpC protein was initially found as a
product of mouse testicular cDNA and shown to be a mammalian
homologue of Xenopus germ cell-specific nucleic acid-binding
protein FRGY2 (Gu et al, 1999). It is expressed in mouse round
spermatids and mature oocytes and is known to interact with both
DNA and RNA. In the present study, we also demonstrated the
expression of dbpC to be predominantly in human male germ cells
and placental trophoblasts as well as in various malignancies.
These features of the tissue distribution and nucleic acid-binding







C     N      C       N
GFP-dbpC
dbpA dbpC dbpB
Figure 4 Expression of dbpC in cultured human seminoma cells. (A)
Demonstration of dbpA, dbpB, and dbpC immunofluorescence in cultured
seminoma NEC8 cells. The dbpC is localised in the cytoplasm of the NEC8
cells, whereas dbpA and dbpB expression is weak. (B) Western blotting
analysis of dbp expression. dbpC is expressed in the cytoplasmic fraction
(C) but not in the nuclear fraction (N) from human seminoma NEC8 or
Tera cells. dbpB is expressed in both cytoplasmic (C) and nuclear (N)
fractions. The expression of dbpA is weakly detected in the cytoplasm or
nuclei. (C) Expression of GFP-dbpC in NEC8 cells. The green fluorescence
indicating the protein is predominantly located in the cytoplasm.
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sother CT antigens. Although dbpC was also expressed in non-germ
cells (myocardium, skeletal muscle, vascular smooth muscle cells
in the lung, and adrenal cortical cells), its distribution was more
restricted than that of dbpB, which is ubiquitously expressed in
normal human tissues (Kohno et al, 2003). Thus, taken together,
our results indicate that the dbpC would be potentially a novel CT-
associated antigen.
As the expression of the CT antigens is detected in spermato-
gonia or spermatogonial stem cells, the CT antigens could be stem
cell markers for tumour cells (Simpson et al, 2005). In fact,
immunohistochemical analysis has shown that CT antigens such as
MAGE-1, MAGE-3, NY-ESO-1, and CT7 are frequently found in
only a small proportion of cancer tissues (Jungbluth et al, 2000,
2002), an indication that the cancers contain both stem cells and
differentiated cells (Simpson et al, 2005). In terms of human
testicular tumours, many CT antigens including MAGE, GAGE,
PAGE-1, SSX2, NY-ESO-1, LAGE-1, and SCP-1 are also demon-
strated to have higher frequency of expression in seminomas than
in non-seminomas (Yuasa et al, 2001). Therefore, these results
suggest that less-differentiated seminomas would contain more CT
antigen-positive stem cells than any other germ cell tumour or
cancer. In the present study, the seminomas and dysgerminomas
showed a diffuse and intense expression with the highest frequency
(100%) for dbpC among the tumours tested including other non-
seminoma germ cell tumours and carcinomas. Even in the
carcinomas classified as negative for dbpC because of less than
10% positive cells, scattered dbpC-positive cells were detected (not
shown). dbpC would thus be not only a CT antigen but also a
marker of cancer stem cells.
Subcellular localisation of dbpC in seminoma cells
The Western blotting analysis demonstrated that the dbpC protein
was detected in the cytoplasmic fraction of seminoma cell lines
(Figure 4B), and the cytoplasmic localisation of dbpC was
confirmed by exogenous overexpression of GFP-dbpC protein in
the NEC8 cells (Figure 4C). These findings indicate that dbpC
might function mainly in the cytoplasm and be related to the
stability of mRNA and translational regulation in seminoma cells
(Gu et al, 1999).
In summary, we demonstrated that dbpC was dominantly
expressed in normal germ cells and in various malignancies. As the
distribution of this protein is very similar to that of CT antigens,
we suggest dbpC to be a novel CT antigen and a marker for cancer
stem cells.
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